Cytek Biosciences (CTKB) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CTKB SEC filings page.
Cytek Biosciences, Inc. (CTKB) reported $206.7M in revenue over the twelve months to Jun 30, 2026, up 5.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue has stalled while costs have worsened, leaving a formerly lightly leveraged business with shrinking equity and renewed cash outflow.
The business's operating cash flow swung from$25.4M positive in FY2024 to-$4.7M in FY2025 while revenue barely moved, indicating the cash reversal was not driven by sales expansion. Free cash flow made the same turn, from$21.9M to-$8.8M , so FY2025's weaker cash economics were broader than the reported net loss alone.
Revenue was essentially flat, while gross margin fell 3.6 percentage points to
Liabilities climbed
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Cytek Biosciences, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Cytek Biosciences, Inc. has an operating margin of -20.0%, meaning the company loses $20 on every $100 of revenue. This results in a profitability score of 18/100. This is down from -10.2% the prior year.
Cytek Biosciences, Inc.'s revenue grew a modest 0.5% year-over-year to $201.5M. This slow but positive growth earns a score of 38/100.
With a current ratio of 5.04, Cytek Biosciences, Inc. holds $5.04 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 92/100.
Cytek Biosciences, Inc.'s operations used $4.7M of cash, and capex of $4.1M added to the outflow, for a free cash flow shortfall of $8.8M. This results in a cash flow score of 30/100.
Cytek Biosciences, Inc. posts a -19.5% return on equity (ROE), meaning it loses $19 for every $100 of shareholders' equity. This results in a returns score of 22/100. This is down from -1.5% the prior year.
Cytek Biosciences, Inc. scores 4.55, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $777.3M against total liabilities of $119.8M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Cytek Biosciences, Inc. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 operating efficiency signals passes.
Cytek Biosciences, Inc. reported a net loss of $66.5M while operations used $4.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Cytek Biosciences, Inc. reported an operating loss of $40.4M against $474K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Cytek Biosciences, Inc. generated $48.1M in revenue in Q2 2026. This represents an increase of 5.6% from the same quarter a year earlier. Against the prior quarter it is up 9.1%.
Cytek Biosciences, Inc.'s EBITDA was -$9.4M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cytek Biosciences, Inc. reported a net loss of $12.2M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cytek Biosciences, Inc. earned -$0.09 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Cytek Biosciences, Inc. recorded an outflow of $849K in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cytek Biosciences, Inc. held $73.8M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Margins & Returns
Cytek Biosciences, Inc.'s gross margin was 58.9% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 6.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 10.7 percentage points.
Cytek Biosciences, Inc.'s operating margin was -23.7% in Q2 2026, reflecting core business profitability. This is down 0.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 18.1 percentage points.
Cytek Biosciences, Inc.'s net profit margin was -25.3% in Q2 2026, showing the share of revenue converted to profit. This is down 13.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 17.5 percentage points.
Cytek Biosciences, Inc.'s quarterly ROE was -3.8% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 2.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.0 percentage points.
Capital Allocation
Cytek Biosciences, Inc. invested $9.7M in research and development in Q2 2026. This represents an increase of 10.4% from the same quarter a year earlier. Against the prior quarter it is up 1.4%.
Cytek Biosciences, Inc. repurchased no shares in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cytek Biosciences, Inc. invested $2.2M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 40.5% from the same quarter a year earlier. Against the prior quarter it is up 2.2%.
CTKB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $48.1M+5.6% | $44.1M+6.5% | $62.1M+8.1% | $52.3M+1.5% | $45.6M-2.2% | $41.5M-7.6% | $57.5M-1.3% | $51.5M+7.3% |
| Cost of Revenue | $19.8M-8.9% | $22.9M+7.4% | $29.3M+22.8% | $24.7M+10.0% | $21.7M+2.6% | $21.3M-2.5% | $23.8M-5.4% | $22.5M+8.0% |
| Gross Profit | $28.3M+18.7% | $21.3M+5.4% | $32.9M-2.3% | $27.6M-5.0% | $23.9M-6.2% | $20.2M-12.4% | $33.7M+1.8% | $29.0M+6.7% |
| R&D Expenses | $9.7M+10.4% | $9.6M-1.2% | $9.0M-7.8% | $9.0M-9.4% | $8.8M-11.7% | $9.7M-0.7% | $9.7M-10.6% | $9.9M-11.5% |
| SG&A Expenses | $30.0M+16.9% | $30.1M+18.5% | $29.5M+40.9% | $27.8M+18.9% | $25.7M+7.1% | $25.4M+6.1% | $20.9M-6.1% | $23.4M+4.2% |
| Operating Income | -$11.4Mn/m | -$18.5Mn/m | -$5.6M-287.3% | -$9.2Mn/m | -$10.6Mn/m | -$15.0Mn/m | $3.0Mn/m | -$4.2Mn/m |
| EBITDA | -$9.4Mn/m | -$16.6Mn/m | -$3.7M-175.3% | -$7.3Mn/m | -$8.7Mn/m | -$13.1Mn/m | $4.9M+224.2% | -$2.4Mn/m |
| Interest Expense | $281K-32.1% | $262K-10.0% | -$725Kn/m | $494K+315.1% | $414K+209.0% | $291K-34.0% | -$5.9M-1605.8% | $119K-80.0% |
| Income Tax | $515Kn/m | $1.5M+997.8% | $40.0M+5789.0% | -$2.3Mn/m | -$1.2M-136.7% | $136Kn/m | $680Kn/m | -$784K-134.5% |
| Net Income | -$12.2Mn/m | -$18.9Mn/m | -$44.1M-557.1% | -$5.5M-682.1% | -$5.6Mn/m | -$11.4Mn/m | $9.6M+75.2% | $941Kn/m |
| EPS (Basic) | -$0.09n/m | -$0.15n/m | -$0.34-585.7% | -$0.04-500.0% | -$0.04n/m | -$0.09n/m | $0.07+75.0% | $0.01n/m |
| EPS (Diluted) | -$0.09n/m | -$0.15n/m | -$0.34-585.7% | -$0.04-500.0% | -$0.04n/m | -$0.09n/m | $0.07+75.0% | $0.01n/m |
| Diluted Shares (Avg) | 129M+2.0% | 129M+0.3% | N/A | 128M-3.9% | 127M-3.4% | 128M-2.0% | N/A | 133M-2.5% |
CTKB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $446.9M-9.4% | $449.1M-6.9% | $461.5M-7.6% | $494.9M+0.8% | $493.3M+2.0% | $482.6M-1.9% | $499.5M+1.0% | $491.2M-5.4% |
| Current Assets | $377.9M-1.3% | $379.3M-0.3% | $392.0M-1.1% | $388.5M-0.4% | $382.8M-0.3% | $380.5M-2.1% | $396.4M+1.1% | $390.2M-7.6% |
| Cash & Equivalents | $73.8M-2.2% | $65.7M-31.1% | $90.9M-8.0% | $93.3M-42.5% | $75.5M-57.6% | $95.3M-43.5% | $98.7M-41.0% | $162.3M-0.8% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $52.3M+5.6% | $49.8M+9.8% | $48.4M+10.3% | $51.6M+10.4% | $49.5M-1.2% | $45.3M-17.2% | $43.9M-27.9% | $46.8M-30.0% |
| Accounts Receivable | $49.7M-11.6% | $51.9M-5.7% | $62.5M+3.2% | $56.6M+7.6% | $56.2M+26.0% | $55.0M+9.4% | $60.6M+8.3% | $52.6M-5.0% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $16.7M-0.1% | $16.7M+0.1% | $16.7M+0.2% | $16.7M+3.2% | $16.7M+3.2% | $16.7M+3.1% | $16.7M+3.0% | $16.2M-1.7% |
| Total Liabilities | $125.0M+8.0% | $121.5M+18.0% | $119.8M+15.5% | $116.3M+10.0% | $115.8M+22.4% | $103.0M+3.5% | $103.8M+2.3% | $105.8M+1.8% |
| Current Liabilities | $84.3M+15.1% | $80.9M+19.6% | $77.8M+15.0% | $75.2M+19.8% | $73.3M+39.9% | $67.7M+21.8% | $67.7M+20.3% | $62.8M+7.0% |
| Non-Current Liabilities | $40.6M-4.3% | $40.5M+14.9% | $42.0M+16.3% | $41.1M-4.2% | $42.5M+0.6% | $35.3M-19.6% | $36.1M-20.1% | $43.0M-5.0% |
| Total Equity | $322.0M-14.7% | $327.6M-13.7% | $341.7M-13.6% | $378.6M-1.8% | $377.6M-3.0% | $379.6M-3.3% | $395.7M+0.7% | $385.5M-7.2% |
| Retained Earnings | -$132.8Mn/m | -$120.6Mn/m | -$101.7Mn/m | -$57.7Mn/m | -$52.2Mn/m | -$46.6Mn/m | -$35.2Mn/m | -$44.8Mn/m |
Not reported in any period shown, so not listed: Long-Term Debt.
CTKB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.4M+1165.7% | -$2.7Mn/m | -$771K-138.6% | -$3.9M-129.5% | $108K-98.3% | -$125K-103.2% | $2.0M-79.0% | $13.2Mn/m |
| Depreciation & Amortization | $2.0M+5.3% | $1.9M-0.5% | $1.9M+2.3% | $1.9M+5.6% | $1.9M+5.6% | $1.9M+10.4% | $1.9M+13.7% | $1.8M0.0% |
| Stock-Based Compensation | $5.3M-21.4% | $4.9M-26.7% | N/A | $5.6M-20.1% | $6.8M-5.0% | $6.6M+17.6% | N/A | $7.1M+22.5% |
| Capital Expenditures | $2.2M+40.5% | $2.2M+155.4% | $1.0M+12.0% | $657K-35.0% | $1.6M+49.8% | $849K+49.7% | $894K-40.4% | $1.0M-24.0% |
| Free Cash Flow | -$849Kn/m | -$4.9Mn/m | -$1.8M-260.7% | -$4.6M-137.3% | -$1.5M-128.5% | -$974K-128.7% | $1.1M-86.2% | $12.2Mn/m |
| Investing Cash Flow | $7.0Mn/m | -$27.1M-386.5% | -$1.8Mn/m | $18.9Mn/m | -$16.4M-911.7% | $9.5Mn/m | -$63.4M-318.2% | -$15.8M-136.7% |
| Financing Cash Flow | -$814Kn/m | $4.0Mn/m | -$1.2Mn/m | $1.9Mn/m | -$2.6Mn/m | -$11.5M-815.7% | -$3.6Mn/m | -$12.1Mn/m |
| Share Buybacks | $0-100.0% | $0-100.0% | -$34K-99.5% | -$29K-99.8% | $4.5M+67.0% | $10.6Mn/m | $7.0M-79.8% | $11.9M+41.2% |
Not reported in any period shown, so not listed: Dividends Paid.
CTKB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 58.9%+6.5pp | 48.2%-0.5pp | 52.9%-5.6pp | 52.7%-3.6pp | 52.3%-2.2pp | 48.6%-2.7pp | 58.6%+1.8pp | 56.3%-0.3pp |
| Operating Margin | -23.7%-0.4pp | -41.8%-5.7pp | -9.0%-14.2pp | -17.6%-9.3pp | -23.3%-5.0pp | -36.1%-12.2pp | 5.2%+5.4pp | -8.3%+5.1pp |
| Net Margin | -25.3%-13.0pp | -42.8%-15.2pp | -70.9%-87.7pp | -10.5%-12.3pp | -12.2%+10.1pp | -27.5%-13.8pp | 16.8%+7.3pp | 1.8%+15.3pp |
| Return on Equity | -3.8%-2.3pp | -5.8%-2.8pp | -12.9%-15.3pp | -1.5%-1.7pp | -1.5%+1.2pp | -3.0%-1.4pp | 2.4%+1.0pp | 0.2%+1.8pp |
| Return on Assets | -2.7%-1.6pp | -4.2%-1.8pp | -9.6%-11.5pp | -1.1%-1.3pp | -1.1%+1.0pp | -2.4%-1.1pp | 1.9%+0.8pp | 0.2%+1.4pp |
| Current Ratio | 4.48-0.7x | 4.69-0.9x | 5.04-0.8x | 5.17-1.0x | 5.22-2.1x | 5.62-1.4x | 5.86-1.1x | 6.21-1.0x |
| Liabilities-to-Equity | 0.39+0.1x | 0.37+0.1x | 0.35+0.1x | 0.310.0x | 0.31+0.1x | 0.270.0x | 0.260.0x | 0.270.0x |
| Asset Turnover | 0.110.0x | 0.100.0x | 0.130.0x | 0.110.0x | 0.090.0x | 0.090.0x | 0.120.0x | 0.100.0x |
| FCF Margin | -1.8%+1.5pp | -11.1%-8.8pp | -2.9%-4.8pp | -8.7%-32.4pp | -3.2%-14.3pp | -2.4%-9.9pp | 1.9%-11.8pp | 23.7%+35.3pp |
Not reported in any period shown, so not listed: Debt-to-Equity.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Cytek Biosciences, Inc. CTKB | FY2025 | $201.5M | -$66.5M | -33.0% | $777.3M | 45/100 |
| Standard BioTools Inc. LAB | FY2025 | $85.3M | -$74.9M | -87.8% | $236.8M | 45/100 |
| OrthoPediatrics Corp. KIDS | FY2025 | $236.3M | -$39.6M | -16.8% | $627.2M | 56/100 |
| Varex Imaging Corporation VREX | FY2025 | $844.6M | -$70.3M | -8.3% | $781.8M | 36/100 |
Where Cytek Biosciences, Inc. Ranks
Frequently Asked Questions
What is Cytek Biosciences, Inc.'s annual revenue?
Cytek Biosciences, Inc. (CTKB) reported $201.5M in total revenue for fiscal year 2025. This represents a 0.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cytek Biosciences, Inc.'s revenue growing?
Cytek Biosciences, Inc. (CTKB) revenue grew by 0.5% year-over-year, from $200.5M to $201.5M in fiscal year 2025.
Is Cytek Biosciences, Inc. profitable?
No, Cytek Biosciences, Inc. (CTKB) reported a net loss of $80.6M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net loss of $66.5M, with a net profit margin of -33.0%.
What is Cytek Biosciences, Inc.'s EBITDA?
Cytek Biosciences, Inc. (CTKB) had EBITDA of -$32.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cytek Biosciences, Inc.'s gross margin?
Cytek Biosciences, Inc. (CTKB) had a gross margin of 51.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Cytek Biosciences, Inc.'s operating margin?
Cytek Biosciences, Inc. (CTKB) had an operating margin of -20.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Cytek Biosciences, Inc.'s net profit margin?
Cytek Biosciences, Inc. (CTKB) had a net profit margin of -33.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Cytek Biosciences, Inc.'s return on equity (ROE)?
Cytek Biosciences, Inc. (CTKB) has a return on equity of -19.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cytek Biosciences, Inc.'s free cash flow?
Cytek Biosciences, Inc. (CTKB) recorded an outflow of $8.8M in free cash flow during fiscal year 2025. This represents a -140.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cytek Biosciences, Inc.'s operating cash flow?
Cytek Biosciences, Inc. (CTKB) recorded an outflow of $4.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Cytek Biosciences, Inc.'s total assets?
Cytek Biosciences, Inc. (CTKB) had $461.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cytek Biosciences, Inc.'s capital expenditures?
Cytek Biosciences, Inc. (CTKB) invested $4.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Cytek Biosciences, Inc. spend on research and development?
Cytek Biosciences, Inc. (CTKB) invested $36.5M in research and development during fiscal year 2025.
What is Cytek Biosciences, Inc.'s current ratio?
Cytek Biosciences, Inc. (CTKB) had a current ratio of 5.04 as of fiscal year 2025, which is generally considered healthy.
What is Cytek Biosciences, Inc.'s liabilities-to-equity ratio?
Cytek Biosciences, Inc. (CTKB) had a liabilities-to-equity ratio of 0.35 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is Cytek Biosciences, Inc.'s return on assets (ROA)?
Cytek Biosciences, Inc. (CTKB) had a return on assets of -14.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cytek Biosciences, Inc.'s P/E ratio?
Cytek Biosciences, Inc. (CTKB) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $777.3M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Cytek Biosciences, Inc.'s price-to-sales ratio?
Cytek Biosciences, Inc. (CTKB) trades at 3.8x sales, its market capitalization divided by $206.7M revenue, trailing 12 months to June 30, 2026. The market capitalization is $777.3M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Cytek Biosciences, Inc.'s Altman Z-Score?
Cytek Biosciences, Inc. (CTKB) has an Altman Z-Score of 4.55, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Cytek Biosciences, Inc.'s Piotroski F-Score?
Cytek Biosciences, Inc. (CTKB) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cytek Biosciences, Inc.'s earnings high quality?
Cytek Biosciences, Inc. (CTKB) reported a net loss of $66.5M while operations used $4.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Cytek Biosciences, Inc. cover its interest payments?
Cytek Biosciences, Inc. (CTKB) reported an operating loss of $40.4M against $474K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Cytek Biosciences, Inc.?
Cytek Biosciences, Inc. (CTKB) scores 45 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.